27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- XORTX Therapeutics Inc (NASDAQ:XRTX) has announced topline results from Part 1 of the three-part Pharmacokinetics Bridging Study – XRX-OXY-101.
- The data showed a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation compared to a control formulation.
- In addition, accompanying the improved bioavailability findings in Part 1 of the trial was a clean safety and pharmacologic profile with no drug-related adverse or serious adverse events related to oral administration of oxypurinol.
- Recruitment, administration of a single oral dose of drug formulation, blood sampling, and bioanalytical evaluation were conducted in Part 1 of the trial to characterize the pharmacokinetics and bioavailability of proprietary formulations ahead of the planned Phase 3 trial in autosomal dominant polycystic kidney disease (ADPKD).
- "Pharmacokinetic modeling of this data will provide additional information to guide decision making as we plan and execute the development of the XRx-008 program..," said Allen Davidoff, CEO of XORTX.
- The company plans to start dosing in Part 2 of the XRX-OXY-101 this week.
- Price Action: XRTX shares are up 84.55% at $2.27 during the premarket session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!